Brief: Otsuka Holdings Announces Positive Interim Results From Phase 3 Trial Of Sibeprenlimab For Treatment Of Immunoglobulin A Nephropathy In Adults
22/10/2024 08:02
Oct 22 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* POSITIVE INTERIM RESULTS FROM PHASE 3 TRIAL OF
SIBEPRENLIMAB FOR
TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY IN ADULTS
Source text for Eikon: ID:nTSvv7a556
Further company coverage: 4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug